46 related articles for article (PubMed ID: 9459205)
1. Anti-HER2 immunoliposomes for targeted therapy of human tumors.
Park JW; Hong K; Kirpotin DB; Meyer O; Papahadjopoulos D; Benz CC
Cancer Lett; 1997 Oct; 118(2):153-60. PubMed ID: 9459205
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.
Feng X; Wen Z; Zhu X; Yan X; Duan Y; Huang Y
Adv Sci (Weinh); 2024 May; 11(17):e2307865. PubMed ID: 38355309
[TBL] [Abstract][Full Text] [Related]
3. Development of immunoliposomes containing cytotoxic gold payloads against HER2-positive breast cancers.
Ahad A; Aftab F; Michel A; Lewis JS; Contel M
RSC Med Chem; 2024 Jan; 15(1):139-150. PubMed ID: 38283233
[TBL] [Abstract][Full Text] [Related]
4. Augmented antitumor immune responses of HER2-targeted pyroptotic induction by long-lasting recombinant immunopyroptotins.
Xing Y; Zhang F; Yang T; Yin C; Yang A; Yan B; Zhao J
Heliyon; 2024 May; 10(9):e30444. PubMed ID: 38737283
[TBL] [Abstract][Full Text] [Related]
5. Chimeric nanobody-decorated liposomes by self-assembly.
Rahman MM; Wang J; Wang G; Su Z; Li Y; Chen Y; Meng J; Yao Y; Wang L; Wilkens S; Tan J; Luo J; Zhang T; Zhu C; Cho SH; Wang L; Lee LP; Wan Y
Nat Nanotechnol; 2024 Feb; ():. PubMed ID: 38374413
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in mRNA cancer vaccines.
Yao R; Xie C; Xia X
Hum Vaccin Immunother; 2024 Dec; 20(1):2307187. PubMed ID: 38282471
[TBL] [Abstract][Full Text] [Related]
7. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now.
Fulton MD; Najahi-Missaoui W
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047585
[TBL] [Abstract][Full Text] [Related]
8. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.
Spicer CD; Jumeaux C; Gupta B; Stevens MM
Chem Soc Rev; 2018 May; 47(10):3574-3620. PubMed ID: 29479622
[TBL] [Abstract][Full Text] [Related]
9. Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
[TBL] [Abstract][Full Text] [Related]
10. Efficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation.
Shigehiro T; Kasai T; Murakami M; Sekhar SC; Tominaga Y; Okada M; Kudoh T; Mizutani A; Murakami H; Salomon DS; Mikuni K; Mandai T; Hamada H; Seno M
PLoS One; 2014; 9(9):e107976. PubMed ID: 25264848
[TBL] [Abstract][Full Text] [Related]
11. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme.
Mortensen JH; Jeppesen M; Pilgaard L; Agger R; Duroux M; Zachar V; Moos T
J Drug Deliv; 2013; 2013():209205. PubMed ID: 24175095
[TBL] [Abstract][Full Text] [Related]
12. Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors.
Sugiyama T; Asai T; Nedachi YM; Katanasaka Y; Shimizu K; Maeda N; Oku N
PLoS One; 2013; 8(6):e67550. PubMed ID: 23840738
[TBL] [Abstract][Full Text] [Related]
13. Immunoconjugates and long circulating systems: origins, current state of the art and future directions.
Koshkaryev A; Sawant R; Deshpande M; Torchilin V
Adv Drug Deliv Rev; 2013 Jan; 65(1):24-35. PubMed ID: 22964425
[TBL] [Abstract][Full Text] [Related]
14. Targeted imaging and therapy of brain cancer using theranostic nanoparticles.
Bhojani MS; Van Dort M; Rehemtulla A; Ross BD
Mol Pharm; 2010 Dec; 7(6):1921-9. PubMed ID: 20964352
[TBL] [Abstract][Full Text] [Related]
15. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
16. Cellular uptake of electron paramagnetic resonance imaging probes through endocytosis of liposomes.
Burks SR; Barth ED; Halpern HJ; Rosen GM; Kao JP
Biochim Biophys Acta; 2009 Oct; 1788(10):2301-8. PubMed ID: 19712666
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
[TBL] [Abstract][Full Text] [Related]
18. Local and average gloss from flat-faced sodium chloride tablets.
Juuti M; van Veen B; Peiponen KE; Ketolainen J; Kalima V; Silvennoinen R; Pakkanen TT
AAPS PharmSciTech; 2006 Jan; 7(1):E7. PubMed ID: 16584166
[TBL] [Abstract][Full Text] [Related]
19. Designing of 'intelligent' liposomes for efficient delivery of drugs.
Voinea M; Simionescu M
J Cell Mol Med; 2002; 6(4):465-74. PubMed ID: 12611636
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.
Marty C; Odermatt B; Schott H; Neri D; Ballmer-Hofer K; Klemenz R; Schwendener RA
Br J Cancer; 2002 Jul; 87(1):106-12. PubMed ID: 12085265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
